Stereotaxis will report its Q4 and full-year 2025 results on March 9, forecasting a $0.06 per-share loss on $9.15 million in revenue, representing a 33.3% narrower loss and 44.3% sales increase year over year.

The company launched a robotic electrophysiology program at Klinikum Fürth, marking its entry into Germany’s electrophysiology market and showcasing its cardiac mapping and ablation technology in a leading hospital setting.